The newest treatments for advanced and metastatic prostate cancer incorporate highly sophisticated precision medicine tools, including targeted radioligand therapies like Lutetium-177 PSMA-617 (Pluvicto), advanced androgen receptor pathway inhibitors, immunotherapy combinations, and PARP inhibitors for patients carrying specific genetic mutations like BRCA. Radioligand therapy represents a major breakthrough by delivering precision radiation directly to cancer cells expressing prostate-specific membrane antigen throughout the body while sparing healthy tissue. Clinical trials are also actively investigating novel combination therapies, personalized cancer vaccines, and cellular immunotherapies to extend survival and improve quality of life for patients with advanced disease.